Scientific deep-dive
GLP-1s in People Being Treated for Cancer
Lower mortality and fewer hospitalizations than metformin, at a hazard ratio of 0.875. A second comparison against insulin produced a bigger number, and the bigger number is the less trustworthy one.
People with both diabetes and cancer who took GLP-1 drugs had lower all-cause mortality and fewer hospitalizations than those on metformin, with a hazard ratio of 0.875.[1] A second analysis, comparing people newly started on a GLP-1 against people newly started on insulin, produced a bigger number. The choice of comparator is a reason to be suspicious of it.
What was found
| Comparison | Hazard ratio |
|---|---|
| GLP-1 vs metformin (monotherapy setting) | 0.875 (95% CI 0.778–0.985), p=0.0268 |
| Newly started GLP-1 vs newly started insulin | 0.786 (95% CI 0.662–0.934), p=0.0062 |
Secondary analyses found lower rates of all-cause hospitalization, sepsis, major adverse cardiovascular events, pulmonary embolism and pneumonia. Subanalyses stratified by body mass index and HbA1c did not reach statistical significance.[1]
Which number to trust
The metformin comparison is the more believable one, and it is the smaller. Metformin is typically first-line and given to people whose diabetes is relatively well controlled, which makes them a reasonably fair comparison group.
Insulin is not. Being on insulin usually marks longer-standing, harder-to-control diabetes and more complications. Comparing a GLP-1 against insulin measures, in part, how sick each group already was before anyone counted a death.
Against insulin the hazard ratio was 0.786; against metformin, the fairer comparison, it was 0.875.
We covered this at length in the cancer cohorts article, where a study reported 91% lower breast cancer mortality against insulin users and nothing at all against a modern comparator in the same paper. The same bias is at work here, but the effect size is far more modest, which is itself reassuring about this study’s quality. Studying people without diabetes removes that comparator problem, though a cohort that did so followed people for a median of only two years.
The subanalyses that failed
Stratifying by BMI and HbA1c did not reach significance.[1] That matters because it leaves the two most obvious explanations for how the drug might help, weight loss and glycemic control, neither confirmed nor ruled out. If the benefit were driven by either, you would expect it to track them, and these subanalyses could not show whether it does.
It may simply be that those subgroups were too small to show anything. But it means the study cannot tell you why the association exists, only that it does, in a design that cannot establish causation anyway.
What this changes for a patient
- Nothing on its own. No GLP-1 is indicated for cancer, and the authors call for prospective, well-controlled studies. What else has been published for people after cancer is collected in ten studies on GLP-1s after cancer.
- It is reassuring about continuation. People with diabetes who develop cancer often wonder whether to stop everything metabolic. This does not suggest harm.
- The hospitalization and infection findings are relevant to cancer care specifically, where sepsis and pneumonia are major causes of treatment interruption. That is consistent with the infection study, here seen in a much sicker population.
- It belongs with the oncologist, who is weighing appetite, nutrition and treatment tolerance in a way no general finding addresses.
Frequently Asked Questions
References
- 1.Mahadevan A, Vosooghi A, Arora JS, et al. GLP-1 receptor agonists in patients with cancer are associated with reduced all-cause mortality and hospitalization The Journal of Clinical Endocrinology and Metabolism. 2026. PMID: 41482652.
Compare the sellers
Related research
GLP-1s and Cancer: What the Cohorts Actually Show
One study found breast cancer mortality 91% lower on GLP-1s than on insulin, and no difference at all against SGLT2 inhibitors. The comparison group produced the result. What is known, and how to read this kind of evidence.
7 min read
Cancer Risk in People Without Diabetes
A study in obese adults without diabetes found 41% lower incidence of obesity-associated cancers. The median follow-up was two years, far too short to establish that a drug prevented anything.
6 min read
GLP-1s and Cancer: The Randomized Answer
Randomized evidence finds little or no effect on obesity-related cancers: pancreatic somewhere between 9 fewer and 6 more per 10,000. The trials were not designed to look for cancer and had short follow-up.
6 min read
The Group That Lost Least Did Best
A study compared surgery, semaglutide and a lifestyle program in young women with endometrial cancer. The group that lost the least weight had the highest tumor remission rate, and that is almost certainly not what it looks like.
6 min read
Are GLP-1s Longevity Drugs? What the Death and Outcome Data Show
GLP-1 drugs lower deaths from any cause by about 12% in people with heart disease, diabetes or kidney disease. No trial has tested them in healthy adults or measured lifespan. SELECT, FLOW, LEADER, dementia, cancer and muscle, in one place.
11 min read
Losing Fast Early: What It Predicts
Rapid responders in SURMOUNT-5, those down 15% or more at week 24, reported more gastrointestinal side effects and completed treatment at a similar rate to everyone else. The likely explanation is that fast loss and nausea reflect the same underlying response.
5 min read
Where to get GLP-1 online, safely: sellers our editors have checked
These are telehealth sellers our editors have checked. For each one we hold a price, the form the drug comes in, and the states it reaches.
No insurance needed · vetted by our editors
Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more
ShedRx
Oral orforglipron alongside the injectables
From $149/mo + membership
Get started →Sesame Care
Oral orforglipron alongside the injectables
From $149/mo + care fee
Get started →Collective
Flat any-dose pricing, if you can absorb a $199 annual membership on top
From $59/mo + membership
Get started →